Evia Bio develops a non-DMSO cryopreservation platform utilizing all-natural organic compounds and AI-driven customization to enhance cell integrity during storage. This technology addresses the limitations of traditional cryoprotectants, improving the viability of cells for clinical applications in the growing cell therapy market.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cryopreservation methods often rely on dimethyl sulfoxide (DMSO), which can be toxic to cells and limit their viability for clinical applications, especially in the rapidly growing cell therapy market. Existing cryopreservation protocols may not be optimized for specific cell types, leading to inconsistent results and reduced therapeutic efficacy.
Solution
Evia Bio offers a non-DMSO cryopreservation platform that utilizes all-natural organic compounds and AI-driven customization to enhance cell integrity during storage. Their technology aims to improve cell viability and functionality post-thaw, addressing the limitations of traditional cryoprotectants. By optimizing cryopreservation protocols for specific cell types, Evia Bio seeks to unlock the full potential of emerging life-saving therapies and improve patient safety at the point of care. The platform provides custom-fit services to improve cell performance, starting with an assessment of current protocols.
Target Audience
Evia Bio's primary customers are cell therapy companies looking to advance their products to clinical trials and commercialization.
Features
- Non-DMSO cryoprotectant solutions utilizing all-natural organic compounds
- AI-driven customization of cryopreservation protocols for specific cell types
- Enhanced cell integrity and viability post-thaw
- Assessment and evaluation of current cryopreservation protocols
- Custom-fit services to improve cell performance